在接受皮肤冠状动脉干预的患者中,医疗保险支付修饰技术,2021-2022年
medRxiv : the preprint server for health sciences
|January 27, 2025
概括
对于接受皮肤冠状动脉干预 (PCI) 的急性心肌梗塞 (AMI) 患者的新冠冠状动脉静脉缩 (IVL) 显著增加了医疗保险支付. 需要进一步的研究来确认IVL和其他修饰技术是否改善了患者的治疗结果,以证明更高的新技术附加支付 (NTAP) 是合理的.
科学领域:
- 心血管医学和干预性心脏病学
- 卫生经济学和报销政策
背景情况:
- 美国医疗保险和医疗补助服务中心 (CMS) 新技术附加支付 (NTAP) 计划鼓励昂贵的新医疗技术.
- 2021年,FDA突破性设备计划 (BDP) 指定技术的"实质性临床改善"标准被放弃.
- 本研究检查了对冲击波C2冠状动脉静脉透症 (IVL) 导管的支付,这是一种用于PCI期间用于急性心肌梗塞 (AMI) 期间修饰的BDP装置.
研究的目的:
- 描述风险标准化的医疗保险支付,用于涉及在PCI期间对AMI进行修饰的住院治疗.
- 为了比较与冠状动脉IVL相关的支付与其他修改技术和没有修改.
主要方法:
- 分析2021年1月至2022年12月期间接受PCI的AMI住院的医疗保险受益人.
- 分为四组分层:没有修饰,旋转切除术 (RA),轨道切除术 (OA) 和冠状动脉IVL.
- 评估风险标准化30天的医疗保险支付,包括设施,医生和急性后护理费用.
主要成果:
- 总共分析了87,238名患者;IVL在1.9%的病例中使用,随着时间的推移使用量增加.
- 接受修饰技术的患者的医疗保险支付中位数总风险标准化支付明显高于没有接受修饰技术的患者 (27,579美元IVL vs 19,115美元; p<0.001).
- 最大的支付差异观察到在指数利支付中.
结论:
- 在AMI患者的PCI期间冠状动脉IVL与医疗保险支付的显著增加有关.
- 需要进一步的研究来确定IVL和其他修饰技术是否能改善接受PCI的AMI患者的治疗结果.
- 这些发现凸显了评估临床益处的必要性,以证明可能更高的NTAP补偿合理.
更多相关视频
08:02Author Spotlight: Enhanced Quantification of Cardiovascular Calcification Progression for Longitudinal Micro PET/CT Studies in Small Research Animals
Published on: November 15, 2024
504
11:30A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
1.9K
相关概念视频
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
448
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
448
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
01:27Parentral Nutrition: Centeral and Peripheral Parental Nutrition
96
Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
96